Diabetes, Vol 34, Issue 12 1283-1287, Copyright © 1985 by American Diabetes Association

ARTICLES

The effect of met-enkephalin and naloxone on somatostatin and insulin secretion from the isolated, perfused rat pancreas

D Di Scala-Guenot and CH McIntosh

The effect of met-enkephalin and the opiate antagonist, naloxone, on somatostatin and insulin secretion from the isolated, perfused rat pancreas has been studied during perfusion with 300 mg/dl glucose. In response to a gradient of met-enkephalin from 0 to 10(-5) M, release of somatostatin was inhibited at low concentrations and stimulated at high concentrations. However, both low and high concentrations of metenkephalin stimulated insulin secretion. A gradient of met-enkephalin from 0 to 10(-6) M caused only an inhibition of somatostatin release, whereas insulin release was stimulated. The effects of met-enkephalin on somatostatin release were antagonized by naloxone (10(-6) M). The metenkephalin-induced insulin secretion was partially, but not completely, blocked by naloxone. Naloxone (10(-6) M) alone changed the endocrine secretions by decreasing somatostatin release and by stimulating insulin release. Met-enkephalin may, therefore, be a physiologic regulator of pancreatic endocrine secretion.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. P. Li, K. Y. Lee, T.-M. Chang, and W. Y. Chey MEK inhibits secretin release and pancreatic secretion: roles of secretin-releasing peptide and somatostatin Am J Physiol Gastrointest Liver Physiol, May 1, 2001; 280(5): G890 - G896. [Abstract] [Full Text] [PDF]